The National Medical Products Administration (NMPA) of China has approved the new drug application (NDA’) of 伊喜宁® (ebronucimab, PCSK9) for the treatment of primary hypercholesterolemia and mixed hyperlipidemia and heterozygous familial hypercholesterolaemia (HeFH).

China’s National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for its fully human anti-PCSK9 monoclonal antibody ebronucimab (AK102) for 2 indications

AD Pharmaceuticals successfully put its world-class biopharmaceutical base at China-Singapore Guangzhou Knowledge City into operation. The commissioning of the base has prepared AD Pharmaceuticals for the upcoming product commercialization, indicating that AD Pharmaceuticals has entered a new level of development.

AD Pharmaceuticals Co., Ltd. announced that patient enrollment has been completed ahead of schedule for the key registered Phase III clinical trial of the anti-PCSK9 monoclonal antibody Ebronucimab (R&D code: AK102), in the treatment of primary hypercholesterolemia and mixed hyperlipidemia.

Akeso, Inc. announced that it has received approval from the National Medical Products Administration (NMPA) to launch an open, multi-center Phase Ib/II clinical study on the treatment of patients with advanced solid tumors using self-developed Cadonilimab (PD-1/CTLA-4 bispecific antibody, AK104),  a novel, potential next-generation, first-in-class bi-specific PD-1/CTLA-4 immuno-oncology backbone drug independently developed by Akeso, and VEGFR-2 monoclonal antibody (AK109) developed by AD Pharmaceuticals.